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ABSTRACT
Background: Four decades after the Alma-Ata Declaration, strengthening primary health care 
(PHC) remains a priority for health systems, especially in low- and middle-income countries 
(LMICs). Given the prominence of chronic diseases as a global health issue, PHC must include 
a wide range of components in order to provide adequate care.
Objective: To assess PHC preparedness to provide chronic care in Mozambique, Nepal and 
Peru, we used, as ‘tracer conditions’, diabetes, hypertension and a country-specific neglected 
tropical disease with chronic sequelae in each country.
Methods: By implementing a health system assessment, we collected quantitative and 
qualitative data from primary and secondary sources, including interviews of key informants 
at three health-system levels (macro, meso and micro). The World Health Organization’s 
health-system building blocks provided the basis for content analysis.
Results: In total, we conducted 227 interviews. Our findings show that the ambitious policies 
targeting specific diseases lack the support of technical, administrative and financial 
resources. Data collection systems do not allow the monitoring of individual patients or 
provide the health system with the information it requires. Patients receive limited disease- 
specific information. Clinical guidelines and training are either non-existent or not adapted to 
local contexts. Availability of medicines and diagnostic tests at the PHC level is an issue. 
Although medicines available through the public health care system are affordable, some 
essential medicines suffer shortages or are not available to PHC providers. This need, along 
with a lack of clear referral procedures and available transportation, generates financial issues 
for individuals and affects access to health care.
Conclusion: PHC in these LMICs is not well prepared to provide adequate care for chronic 
diseases. Improving PHC to attain universal health coverage requires strengthening the 
identified weaknesses across health-system building blocks.
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In 1978, the Alma-Ata Declaration [1] called for 
strengthening primary health care (PHC) as an 
integral part of developing the health system and 
the community’s role in ensuring healthy popula-
tions. Four decades later, most of the evidence 
about the role of the PHC comes from high- 
income countries [2]; nonetheless, strengthening 
PHC remains a priority for health systems in low- 
and middle-income countries (LMICs) [3]. Given 
the epidemiological transition, with the increase in 
noncommunicable diseases (NCDs) [4,5] in parallel 
with the burden of communicable diseases, PHC 
must be able to deliver care for all health-related 
needs of the population it serves [6]. One specific 
concern in health systems in LMICs is the lack of 
capacity to manage chronic long-term conditions 
that NCDs or communicable diseases cause [7– 
10]. PHC is key to addressing the supply of quality 
health services and the demand factors influencing 
services the population utilises [11]. Although the 
Sustainable Development Goals (SDGs) do not 
directly mention PHC [12], the 2018 Declaration 
of Astana highlighted its relevance: ‘PHC is 
a cornerstone of a sustainable health system for 
universal health coverage and health-related 
SDGs’ [13].
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The causes of NCDs and neglected tropical dis-
eases (NTDs) differ, but both require chronic disease 
management with a focus on continuity of care, reg-
ular access to medicines and health services and 
appropriate patient education [14–16]. This study 
aims to assess PHC preparedness to provide chronic 
care in Mozambique, Nepal and Peru,using specific 
NCDs (diabetes and hypertension) and respective 
country-specific NTDs as ‘tracer conditions’ [17,18]. 
The rationale for using two distinct groups of diseases 
rests on their potential for identifying ‘strengths and 
weakness of services delivery and health systems’ 
[19]. Thus, the study of ‘tracer conditions’ as a tool 
for evaluating PHC preparedness creates a unique 
framework for explaining the challenges of chronic 
care in LMIC settings.
Methods
This study utilised a Rapid Assessment Protocol [20], 
implemented in various LMICs and adapted for this 
study [21–23]. The methodology took a mixed- 
methods approach, included various types of infor-
mants at different levels of the health system (macro, 
meso and micro) and relied on multiple data sources 
and topics of study. We gathered secondary data and 
collected primary data from interviews. The selected 
‘tracer conditions’ were diabetes and hypertension 
(NCDs) for all countries and a country-specific 
NTD: schistosomiasis (Mozambique), leprosy 
(Nepal), and neurocysticercosis (Peru).
Settings
We implemented the study in rural and semi-urban 
communities in Mozambique, Nepal and Peru [24]. 
These LMICs represent three different geographical, 
socio-economic and health-system contexts (Table 1).
Sampling
We purposively selected and enrolled 10 PHC facil-
ities (4 in Mozambique, 4 in Peru and 2 in Nepal) 
based on the following criteria: 1) At least half of 
PHC facilities are located in rural low-income 
areas; 2) Hypertension and diabetes are present in 
the selected PHC facility areas, and the selected 
NTD is endemic in the respective study setting; 3) 
Adequate accessibility (e.g. feasible to reach using 
public transportation) to each PHC facility; 4) PHC 
facilities do not participate in other research pro-
jects; 5) The head of each PHC facility is willing to 
participate in the study.
The selection of participants was purposively and 
followed the ‘snowball’ technique until reaching data 
saturation. Interviewees were key stakeholders at the 
national (macro) and intermediate (meso) level due 
to their role in the health system with experience in 
NCDs or NTDs; or they were patients (or caregivers) 
living with one or more selected diseases or health 
care workers managing people with NCDs or NTDs 
(micro-level). Macro-level interviews included indivi-
duals from the national Ministry of Health, disease- 
specific associations or organizations, and clinical or 
academic opinion leaders. Targeted participants at 
the meso-level were from regional and local health 
offices, public and private laboratories, public and 
private pharmacies and heads of PHC facilities. 
Finally, micro-level interviews focused on PHC work-
ers (physicians, nurses, obstetricians, etc.) and people 
(or caregivers) living with NCDs or NTDs.
Data collection
A questionnaire in English was locally adapted by each 
country team and translated to Spanish in Peru, 
Portuguese in Mozambique and English in Nepal. 
Each country team conducted interviews in the follow-
ing languages: Spanish (Peru); Portuguese and 
Changane (Mozambique); Nepali, Hindi and Maithali 
(Nepal). The fieldwork team in each country, composed 
of five to seven members, had a background in health 
sciences, previous experience conducting interviews in 
community-based projects and the ability to commu-
nicate in the local languages.
One or two researchers in each country trained the 
fieldworkers in their local official language. The train-
ing took over 20 hours and also included the piloting 
Table 1. General information of Mozambique, Nepal and Peru.
Indicator Mozambique Nepal Peru
Country income group (1) Low income Low income Upper middle income
Population (in thousands, year 2018) (1) 29,496 28,088 31,989
Gross Domestic Product (GDP) per capita in US current dollars (year 
2018) (1)
503.3 1,038.7 6,941.2
Life expectancy at birth (year 2018) (1) 60.2 70.5 76.5
Current health expenditure (% of GDP, year 2018) (2) 8.2 5.8 5.2
Physicians (per 10,000 people, year 2018) (2) 0.8 7.5 8.2
Age-standardized NCD mortality rate (per 100,000 population, year 
2018) (2)
783.6 602.3 305.5
Districts with PHC facilities included in the study (population) Moamba (83,879) [25] 
Nlhamankulu (129,306) 
[25]
Baniyani (6,458) [26] 
Itahari (140,517) 
[27]
Montero (6,179) [28] 
Ayabaca (30,852) 
[28]
(1) World Development Indicators [29]; (2) Global Health Observatory data repository [30]. 
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of the interview tools. Other topics covered during 
the training included NCDs and NTDs, interviewing 
techniques, application of tools, ethics, research 
topics and data entry. The fieldwork team conducted 
all micro-level interviews. At the macro and meso 
levels, one or two researchers conducted the inter-
views. All interviews took place between 
December 2016 and August 2017.
The interviews addressed different topics of 
study: 1) National health plans, policies, strategies, 
or action plans for preventing and managing NCDs 
and NTDs; 2) Organizational structure within the 
Ministry of Health related to the selected NCDs and 
NTDs; 3) National budget line for the selected 
NCDs and NTDs; 4) Funding of the selected dis-
eases and financial consequences for patients; 5) 
National surveillance system and registry of the 
selected diseases; 6) National clinical practice guide-
lines about prevention and management of the 
selected diseases at the PHC level; 7) Knowledge 
and training of health-care workers on the selected 
diseases; 8) Availability and price of tests and con-
sumables for the selected diseases; 9) Availability 
and price of essential medicines for the selected 
diseases; 10) Prevention of the selected diseases 
through patient education; 11) Referral process 
information and implementation. In addition to 
these topics, interviews also included other ques-
tions to inform about potential interventions in 
each country [24,31].
Each interviewer recorded the information manu-
ally and entered it using a form in Microsoft Excel. 
Only a small proportion of interviews were recorded, 
especially those related to the macro-level and some 
health-care workers. The information was quantita-
tive (e.g. quantity and price of medicines, equipment, 
and consumables) and qualitative (knowledge and 
opinion on specific topics). We confirmed the avail-
ability of medicines through on-site observation on 
the day of the visit. We recorded the retail prices of 
medicines at the public PHC pharmacy and private 
pharmacies located near the PHC. Secondary data 
sources, mainly policy documents and health reports, 
were provided by the participants or gathered from 
public sources.
A list of the country-specific policy documents and 
secondary sources collected is presented in 
Supplementary material 1. We also prepared a data 
collection and analysis matrix (Supplementary mate-
rial 2) to have a standard structure of topics covered 
and questions used in all countries, thus facilitating 
cross-country comparison. We also used the World 
Health Organization (WHO)’s recommendations on 
monitoring and evaluation framework [32] and 
a manual to investigate NCDs in LMICs [20] to 
identify the topics and core information to include 
in the matrix.
Data analysis
Using the findings from interviews (quantitative and 
qualitative) and secondary sources (policy docu-
ments, reports, technical documents), we conducted 
a content analysis applying the WHO’s health-system 
building blocks [33]. The matrix that shows the data 
collection and analysis (Supplementary material 2) 
presents the collected information, identifies the rele-
vant WHO building block and notes the sources and 
questions. We used the matrix to follow a schematic 
process, to organise data collection and facilitate data 
analysis and cross-country comparisons of the 
selected diseases at the PHC level. We triangulated 
and combined findings from different types of infor-
mants, various types of information and multiple 
sources, to corroborate the information and show 
the informants’ perspectives. Researchers from 
a different country team reviewed the results of 
a country other than their subject country, to con-
tribute to the reflexive process.
The qualitative data came from open-ended ques-
tions designed to provide a deeper understanding of 
the topics of study. After reading and re-reading the 
qualitative data using the Microsoft Excel database, 
each country team prepared a summary of each topic. 
Some interviews were recorded, enabling the extrac-
tion of verbatim quotes. Quantitative data analysis 
used proportions for the availability of medicines 
and median prices to measure affordability. We 
applied the methodology proposed by Health Action 
International and WHO to assess affordability [34], 
calculating the monthly cost of medicines and the 
number of days at the lowest-paid government work-
er’s daily wage that would cover it. First, assuming 
30 days per month, we calculated the monthly treat-
ment cost for each medicine, using its median price 
for the ‘Defined Daily Dose’ in the surveyed facilities 
[35]. Then, we divided the monthly treatment cost by 
the monthly wage for the lowest-paid government 
worker in each country, using the following monthly 
wages for 2018: 4,255 Mozambican Metical in 
Mozambique, 16,230 Nepalese Rupee in Nepal and 
930 Peruvian Sol in Peru.
Ethics
Participation in the study was voluntary, informed 
consent was sought, and ethical approval was 
obtained from: Commission Cantonale d’éthique de 
la recherche (Switzerland); Faculdade de Medicina/ 
Hospital Central de Maputo (Mozambique); Nepal 
Health Research Council (Nepal); and Universidad 
Peruana Cayetano Heredia (Peru). After receiving 
the ethical approval, each country team also 
requested authorization from the concerned health 
authorities and PHC facilities.
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Results
In total, we conducted 227 interviews, averaging 
60 minutes each. (Table 2) The WHO building blocks 
structure the presentation of the interview results and 
secondary data [33].
Governance
Each country had established a functioning unit or 
department in the Ministry of Health responsible for 
NCDs: Mozambique in 2000, Nepal in 2009 and Peru 
in 2004. All NCD departments had shortages of 
human and financial resources. According to some 
policy makers in Mozambique, NCDs had received 
much less attention and insufficient resources than 
programmes for malaria or HIV. These inadequacies 
also characterised the NTD departments in 
Mozambique and Peru. In Mozambique, the NTD 
department covered schistosomiasis; in Peru, the 
remit of the NTD department did not specifically 
include neurocysticercosis. Nepal’s Leprosy Control 
Division, several decades old, had received substantial 
resources from international partners.
Despite the inclusion of NCDs in various strate-
gic documents, some macro-level participants in the 
three countries mentioned insufficient resources 
and low priority of the PHC on addressing NCDs 
as primary pitfalls. Overall, considering the avail-
able resources, plans were called ‘ambitious’. 
Mozambique and Peru had implemented specific 
NCD policies nationwide; in Nepal, the main activ-
ity was the implementation of the WHO Package of 
Essential Noncommunicable Diseases programme 
(WHO-PEN) [36]. Also, Nepal included in the 
Nepal Health Sector Programme-II an ‘Essential 
Healthcare Services’ programme that aimed to pro-
vide a basic package of essential medicines, free to 
patients, at PHC facilities and hospitals. In 
Mozambique, the NTD plan included a wide range 
of activities (e.g. mass drug administration, control 
activities, sanitation and health education). Still, 
only mass drug administration for schistosomiasis, 
which foreign partners funded, was implemented. 
Specific policies for leprosy were formulated and 
implemented in Nepal, also with the support of 
foreign aid. In contrast, Peru had no specific action 
plans for neurocysticercosis.
Macro-level participants in these countries identi-
fied the challenge for both NCDs and NTDs, namely, 
their low capacity for decision-making and planning, 
as well as unrealistic objectives and priorities for the 
PHC level and a lack of an intersectoral vision 
beyond the health sector.
[. . .] policies and guidelines are one thing, and the 
other is the practical dimension [. . .]. I feel that there 
is a need to have a greater involvement and 
commitment at all levels starting from the top-level 
decision-makers. These are very important diseases 
[referring to NCDs], but the attention they are having 
is still inadequate. I know that the country has no 
money, but these [referring to NCDs] should have 
more priority [. . .], without funds we are unable to 
have satisfactory results. (Ministry of Health, 
Mozambique) 
The problem is not the doctor who treats and refers 
the patient, the problem is that when the patient 
returns to the community, he or she becomes sick 
again because the risk factors continue. This part is 
not only from the Ministry of Health, but also from 
the other sectors. The action must be done by calling 
other sectors. Regions would have to determine the 
actions because they are closer to the problem and 
the affected population. (Opinion Leader, Peru) 
Financing
In Mozambique, attention to both NCDs and NTDs 
depended on donor funding. An opinion leader 
highlighted the fact that the available funding was 
insufficient even to cover ‘basic activities’ of the 
departments unless a donor decided to support 
them financially. In Nepal, taxation on tobacco 
and alcohol products constituted the main funding 
source for NCD services; however, no specific lines 
in the public budget existed for attending to dia-
betes or hypertension. The government and donors 
funded Nepal’s Leprosy Control Programme. Peru 
had specific budget lines for ‘treatment and control’ 
of diabetes or hypertension, part of a ‘budgeting for 
results’ programme funded with general revenues. 
However, because it was not part of the NTD stra-
tegic plan, funding to address neurocysticercosis 
was not in the budget allocation for NTDs in 
2017. In Peru, a participant mentioned that the 
PHC level was still significantly underfunded. 
Overall, financing for policy and programmatic 
responses to the selected diseases was insufficient 
in all countries. Moreover, donors in Mozambique 
still play an essential role in funding these activities.
Table 2. Number of interviews conducted per type of infor-
mant at the macro, meso and micro-level.
Health system level Mozambique Nepal Peru
Macro-level interviews: Ministry of 
Health, disease-specific national 
associations or organizations and key 
opinion leaders
9 9 25
Meso-level interviews: Regional and 
local health offices, heads of PHC 
facilities, public/private laboratories and 
pharmacies
20 16 19
Micro-level interviews: Health-care 
workers (physicians, nurses, 
obstetricians, etc.) and people with 
NCDs or NTDs
28 46 54
Total number of interviews: 57 72 98
Number of PHC facilities: 4 2 4
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In the public system, people in Mozambique 
usually paid about US$0.10 for an appointment and 
medicines. However, most patients with diabetes or 
hypertension self-reported having financial problems 
due to their diseases. Some had to buy their medi-
cines in private pharmacies when medication was 
insufficient or unavailable in public facilities. The 
Leprosy Control Programme in Nepal fully covered 
free leprosy treatment, so none of those interviewees 
reported financial hurdles due to leprosy. In Nepal, 
the publicly funded Essential Health Care Services 
programme covers the cost of managing people with 
diabetes and hypertension, providing limited types of 
medicines, free at public facilities. However, some 
patients experienced financial problems when medi-
cines were not available, or they incurred high trans-
portation costs to get to hospitals. The public sector 
in Peru covers costs through the public health insur-
ance programme, Seguro Integral de Salud (SIS). 
Nevertheless, half of the patients with hypertension 
and most patients with diabetes or neurocysticercosis 
related financial problems to their diseases.
We don’t have money for basic activities of the 
department unless a partner with a given interest 
decides to provide some amount [. . .]. (Ministry of 
Health, Mozambique) 
I spent lots of money to manage the disease, and 
even I sold my land. (Person with NCD, Nepal) 
Sometimes I don’t have money to buy medicines and 
I have to stop buying my groceries to be able to buy 
medicines or, in any case, I buy the medicines when 
there is money. (Person with NCD, Peru) 
Data and information system
None of the countries had a nationwide surveillance 
system for all NCDs. Peru started a surveillance sys-
tem for diabetes in 2011, present and still being scaled 
up, but with interruptions. For the selected NTDs in 
Mozambique and Peru, notification is not manda-
tory. According to the interviewees, a national system 
for leprosy surveillance in Nepal is functioning, with 
a Web-based reporting system and active surveillance 
in endemic areas. Although the implementation of 
Mozambique’s Health Management Information 
System (HMIS) started in 2016, PHC providers were 
still recording patient information manually in paper 
files. In Nepal, information on diabetes and hyperten-
sion was recorded in the same registry used for other 
diseases, while for leprosy, the registry of patients’ 
information operated well using the HMIS. In Peru, 
health-care workers used the Health Information 
System and the FUA-SIS form (a health services 
form called ‘Formato único de atención’ in Spanish, 
only for patients affiliated to SIS) to record patient 
diagnoses. Still, this system contains very general 
patient information, including weight, height and 
blood pressure measurements.
PHC facilities in all countries reported that the 
poor management of information created challenges 
regarding planning and requesting resources to 
respond to the population’s needs. According to 
a key opinion leader in Peru, improving the avail-
ability of high-quality data on the disease burden 
would help make better projections possible and jus-
tify a higher budget, to meet the increasing number 
of patients and their needs.
[. . .] schistosomiasis has very low [quality] data, I do 
not know if the problem is that people can not 
diagnose schistosomiasis or are not able to record 
it. (Health-care worker, Mozambique) 
I had a notebook that suddenly disappeared. 
Everything changed when the management [of the 
PHC facility] also changed, but I’ve already made my 
new notebook, I’m going to start filling it in again 
[. . .]. I have a notebook for diabetes and hyperten-
sion, but not for neurocysticercosis. Everything is in 
notebooks, not in a digital system. (Health-care 
worker, Peru) 
Health-care workers
Mozambique had no guidelines for diabetes nor 
schistosomiasis, only specific guidelines for cardio-
vascular diseases, developed in 2011 at the PHC 
level. Consequently, health-care professionals self- 
reported that they based their decisions on their 
own experience. In Nepal, the WHO-PEN protocol 
for the management of diabetes and hypertension in 
PHC was available in the facilities that had imple-
mented the WHO-PEN programme but not yet avail-
able in the studied facilities. For leprosy, clinical 
guidelines were available at PHC facilities. In addi-
tion, clinical guidelines for the detection and manage-
ment of diabetes, hypertension and 
neurocysticercosis were available in Peru. Still, these 
were mainly based on international guidelines and 
not adapted to the local context nor widely dissemi-
nated at the PHC level.
All countries lacked adequate training in diabetes 
and hypertension. Most medical and nonmedical 
health-care workers mentioned that their main 
source of training was their undergraduate studies. 
Health-care workers in Mozambique said that the 
only training for prevention and management of dia-
betes and hypertension they had received was during 
their professional training. Consequently, not all felt 
confident managing these conditions, especially 
regarding preventive measures and diet recommen-
dations for patients with diabetes. However, they felt 
more confident managing schistosomiasis cases, even 
though some providers stated that the training they 
received was insufficient. Though PHC workers in 
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Nepal had inadequate training on diabetes and hyper-
tension, some training on the management of NCDs 
has started in areas where the WHO-PEN package is 
implemented. Nonetheless, according to some health- 
care workers, training for leprosy management last 
occurred a decade ago. In Peru, doctors and some 
nurses are the only ones who receive training at the 
PHC level from the regional health office, but not 
technicians, the main workforce in PHC. Some 
health-care workers said that the last training they 
received occurred ten years ago, with others stating 
that must travel to a large city and finance their 
training on NCDs by themselves. Moreover, they 
had not received appropriate training for preventing, 
diagnosing or managing neurocysticercosis despite its 
being an endemic Peruvian disease. Due to these 
training limitations, health-care workers in Peru felt 
more confident managing hypertension than diabetes 
and neurocysticercosis.
[. . .] we don’t have anything written to guide our 
daily practice, what we know is what we learned 
during our pre-service training and is based on our 
experience [. . .]. (Health-care worker, Mozambique) 
[. . .] trainings for health-care workers on manage-
ment of diabetes and hypertension are inadequate 
and regular trainings for case detection, manage-
ment, and proper counselling are necessary [. . .], 
only health-care workers in upper-level centres of 
accessible areas like Kathmandu and Lalgadh receive 
training, and adequate training is lacking for health- 
care workers at PHC level. (Local health office, 
Nepal) 
I haven’t had a training for ten years [. . .]. Personally, 
I read books on diabetes and hypertension to at least 
have some knowledge. (Health-care worker, Peru) 
Medical technologies
In Mozambique and Peru, all PHC facilities had 
a glucometer but not all the required consumables 
to measure blood glucose levels. In Nepal, gluc-
ometers were not available, but PHC facilities had 
laboratory equipment for glucose testing. Such 
laboratory equipment was present in PHC facilities 
in Mozambique and Peru, but none had the necessary 
reagents. All the facilities in the three countries had at 
least one functioning device to measure blood pres-
sure. In Mozambique, the number of automated 
sphygmomanometers available was insufficient, and 
all countries had problems regarding the availability 
of batteries or calibrated devices.
All PHC facilities in Mozambique had the diag-
nostic tests and necessary consumables for schistoso-
miasis. Only one facility in Peru had the equipment 
and consumables to look for the parasite’s eggs in 
stools. However, for both leprosy and neurocysticer-
cosis, the additional challenge was that diagnostic 
tests require referral to higher levels of the health 
system. For neurocysticercosis, western blot tests 
and computerised tomography scans are only possi-
ble at hospitals. Although clinical symptoms are the 
main basis for a diagnosis of leprosy, a skin smear 
microscopy test sometimes needed for confirmation 
is not performed in PHC.
Availability of medicines remains a challenge in all 
countries (Table 3). Metformin was found in all PHC 
facilities in Mozambique and Nepal and half of the 
facilities in Peru. Glibenclamide was only available in 
Mozambique and half of the facilities in Peru but not 
in Nepal. One of four PHC facilities in Peru and 
a private pharmacy had insulin. PHC facilities and 
private pharmacies in Mozambique and Nepal had no 
insulin. Regarding hypertension, all PHC facilities in 
Mozambique and Nepal had amlodipine, and most 
public pharmacies in Peru had either amlodipine or 
nifedipine. Additionally, half of PHC facilities in 
Mozambique and all public pharmacies in Nepal 
had at least one medicine from the beta-blocker 
group, available in only one PHC facility in Peru. 
Angiotensin-converting enzyme inhibitor was avail-
able in all PHC facilities in Mozambique and Peru 
but not in Nepal, where only private pharmacies had 
enalapril for sale. Thiazide diuretics (hydrochlor-
othiazide) were found in most PHC facilities in 
Mozambique and Peru, but only in private pharma-
cies in Nepal.
Treatment for schistosomiasis in Mozambique is 
available in the public health system, where all PHC 
facilities provided this treatment. In Nepal, medicines 
through the leprosy programme are also highly avail-
able in the public sector. However, except for carba-
mazepine to control seizures, medicines for 
neurocysticercosis, antiparasitic drugs and corticos-
teroids are only partially available in PHC facilities in 
Peru because the treatment is provided only at 
hospitals.
From the collected data, we know that the avail-
ability of some NCDs medicines at public pharmacies 
was ‘irregular’ and ‘hard to predict’ throughout 
the year. Many patients who did not find their med-
icines in the health facility’s pharmacy had to either 
buy them in the private sector or stopped taking their 
treatment until the PHC pharmacy had stock again. 
Sometimes, they could find their medication only in 
pharmacies in large cities.
The other challenge regarding medicines is afford-
ability. In the public health system, except for insulin, 
purchasing medication requires less than one day’s 
wages, meaning that these medicines are affordable if 
they are available (Figs.1–2). Medicines for NCDs 
were affordable in the private sector, except for met-
formin (23.3 days’ wages), glibenclamide (11.6 days’ 
wages) and atenolol (4.8 days’ wages) in 
Mozambique. Peru was the only country with 
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available isophane insulin at one PHC facility and 
one private pharmacy. The treatment with isophane 
insulin required between 12.6 days’ wages (public 
pharmacy) and 19.3 days’ wages (private pharmacy), 
while human insulin, available only at a public facil-
ity, needed almost 31 days’ wages.
Similarly, the treatment for NTDs is unafford-
able when patients must buy their medicines at 
private pharmacies (Figure 3). For schistosomiasis 
in Mozambique, praziquantel is affordable in the 
public sector but can be as high as 3 days’ wages in 
a private pharmacy. For neurocysticercosis, in the 
private sector in Peru, albendazole (3.6 days’ wages) 
and carbamazepine (4.1 days’ wages) were unaf-
fordable, though they were affordable at public 
pharmacies. Meanwhile, the treatment for leprosy 
in Nepal is entirely free and available at PHC 
facilities.
The main constraint, I would not say main, but that 
turns out to be difficult that does not depend much 
on me, is the patient’s lack of medication. [. . .] I ask, 
why are you not taking [medicines], why? ‘Haaa, 
I have no money to buy’, so I’m pretty much help-
less. I cannot send them to the pharmacy because it 
does not have medicines, the patient has no medi-
cine, no money to buy certain medicines. [. . .] we 
have hardly had all of them [medicines for NCDs]. 
(Health-care worker, Mozambique) 
In terms of access to medicines, due to logistical 
problems, they may not have access to medicines 
for periods of time, [. . .] access is not guaranteed 
100%, there are only 6 to 7 months of the year, but 
then they run out. [. . .] the transport of medicines 
is another constraint, especially in remote areas. 
[. . .] the laboratories do not have biosecurity, 
they are tiny, they do not have washing facilities, 
sometimes they do not have water. (Regional 
health office, Peru) 
Table 3. Availability of medicines in the selected PHC facilities.
Mozambique Nepal Peru
Medicines by disease
Public (n = 4) Private (n = 5) Public (n = 2) Private (n = 4) Public (n = 4) Private (n = 2)
n % n % N % N % n % n %
Diabetes
Human insulin (DNA recombinant origin) 0 0% 0 0% 0 0% 0 0% 1 25% 1 50%
Isophane insulin (NPH) 0 0% 0 0% 0 0% 0 0% 1 25% 0 0%
Metformin 4 100% 5 100% 2 100% 0 0% 2 50% 2 100%
Glibenclamide 4 100% 5 100% 0 0% 0 0% 2 50% 1 50%
Hypertension
Calcium channel blockers
Amlodipine 4 100% 0 0% 2 100% 4 100% 2 50% 1 50%
Nifedipine 4 100% 0 0% 0 0% 4 100% 3 75% 0 0%
Beta-blockers
Atenolol 2 50% 5 100% 2 100% 4 100% 0 0% 0 0%
Carvelidol 0 0% 0 0% 0 0% 0 0% 1 25% 0 0%
Angiotensin-converting enzyme inhibitors
Captopril 0 0% 2 40% 0 0% 0 0% 4 100% 2 100%
Enalapril 4 100% 4 80% 0 0% 4 100% 3 75% 2 100%
Thiazide diuretic
Hydrochlorothiazide 4 100% 3 60% 0 0% 4 100% 3 75% 0 0%
Schistosomiasis
Praziquantel 4 100% 3 60% - - - - - - - -
Leprosy
Clofazimine - - - - 2 100% 0 0% - - - -
Dapsone - - - - 2 100% 0 0% - - - -
Rifampicin - - - - 2 100% 0 0% - - - -
Prednisolone - - - - 2 100% 4 100% - - - -
Neurocysticercosis
Antiparasitic drugs - - - - - - - -
Albendazole - - - - - - - - 4 100% 2 100%
Mebendazole - - - - - - - - 4 100% 2 100%
Niclosamide - - - - - - - - 0 0% 0 0%
Praziquantel - - - - - - - - 0 0% 0 0%
Pyrantel - - - - - - - - 0 0% 1 50%
Corticosteroids
Dexamethasone - - - - - - - - 4 100% 2 100%
Prednisone - - - - - - - - 2 50% 2 100%
Anticonvulsants
Carbamazepine - - - - - - - - 3 75% 2 100%
Phenobarbital - - - - - - - - 1 25% 0 0%
Phenytoin sodium - - - - - - - - 1 25% 0 0%
Valproate - - - - - - - - 0 0% 0 0%
Ethosuximide - - - - - - - - 0 0% 0 0%
Gabapentina - - - - - - - - 0 0% 2 100%
Lamotrigine - - - - - - - - 0 0% 0 0%
Other psychotropic/ benzodiazepines
Clonazepam - - - - - - - - 0 0% 1 50%
Diazepam - - - - - - - - 4 100% 0 0%
Lorazepam - - - - - - - - 0 0% 0 0%
*Analysis includes all doses and forms combined. 
** The hyphen means that the fieldworkers did not ask about this medicine because it was not for one of the target diseases in that country. 
GLOBAL HEALTH ACTION 7
Service delivery
Many of the weaknesses described above impact the 
quality of health-care delivery. This study explored 
two areas of service delivery, access to information 
and referrals. These face issues of quality and how the 
information is provided, given the low education 
levels of the population in the study settings. The 
NCD information provided through medical consul-
tations and leaflets mainly focused on lifestyle advice 
and less on treatment: e.g. increasing fruit and vege-
table consumption and physical activity, smoking 
cessation, and decreasing sugar, salt and fried food 
intake. Health-care workers in all countries saw 
NCD-related material and information as inadequate, 
as was information in Peru for neurocysticercosis. 
Health-care professionals and users found the infor-
mation for both schistosomiasis and leprosy ade-
quate. Moreover, all patients with leprosy were 
satisfied with the information provided for preven-
tion, symptomatology and treatment of their diseases, 
usually provided through educational classes, bro-
chures and flipcharts, and they found it useful.
In Peru, almost all the health facilities had 
a flowchart showing the referral process for any 
disease. Most PHC workers said that the referral 
process works effectively, especially for guiding 
patients to appointments or exams at an upper level. 
In these cases, referral appointments are given for the 
next 15–30 days. In contrast, in Mozambique and 
Nepal, referral procedures are unclear. Health-care 
providers in Mozambique highlighted people sent 
back, apparently for not meeting the referral criteria 
and communication problems. Still, health-care pro-
viders at PHC could not manage them. In Nepal, all 
the facilities interviewed had a referral guideline for 
patients with leprosy, a flow chart with the referral 
criteria for patients with symptoms and complica-
tions of leprosy and a map showing the location of 
leprosy referral centres. Participants from Peru and 
Mozambique also highlighted challenges around 
available transportation to regional hospitals, espe-
cially in emergencies. Overall, these issues highlight 
the lack of PHC role definition in delivering services 
for chronic conditions.
The process of referral of analyses sometimes has 
some difficulties because sometimes the analyses do 
not arrive, or was poorly collected [. . .], so if the 
patient appears to have diabetes problems today 
Figure 1. Affordability of medicines for diabetes in the selected sites.
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and we suspect, we can not medicate before we have 
a laboratory confirmation, so this is another process 
that we have to wait for the results to arrive and only 
then we can start to act. (Health-care worker, 
Mozambique) 
Patients with diabetes or hypertension are referred 
by health-care worker according to their knowledge, 
if they feel the case is complicated, with referral note 
written in OPD [out patient services] card [. . .]. In 
Baniyani, the main difficulty for patients when 
referred are transport problems, distance and inap-
propriate road, access and poor economic condition 
of patients [. . .]. Patients are basically advised to go 
to Bhadrapur hospital and BPKIHS [B.P. Koirala 
Institute of Health Sciences], and there is no follow 
up of such cases. (Health-care worker, Nepal) 
The most frequent problems in the referral is not 
having a functioning ambulance or enough fuel, 
sometimes it operates without oxygen, cardio- 
resuscitator, or oximeter [. . .]. (Health-care worker, 
Peru) 
Discussion
This study highlights the complexity and challenges 
of addressing chronic care needs for NCDs and 
NTDs at the PHC level across three LMICs. Using 
different chronic diseases as ‘tracer conditions’ and 
a multilevel health system assessment methodology, 
we found that PHC preparedness in Mozambique, 
Nepal and Peru is still inadequate and insufficient 
in the context of various WHO building blocks. Our 
study especially highlights that health systems in 
LMICs fail to go beyond specific vertical programmes 
or health conditions in moving from the provision of 
acute to chronic care and from single to multiple 
conditions [37,38].
Our results indicate that the ambitious policies in 
place in these countries are not matched by technical, 
administrative and financial resources, except for 
those related to leprosy in Nepal, where there is 
a vertical donor-funded programme. However, verti-
cal approaches in the study countries have not been 
sufficient to strengthen the health systems. Moreover, 
policies do not address intersectoral issues, and ade-
quate and sustainable financing is a challenge. 
Although essential medicines are affordable or free 
in the public sector, they are not widely available at 
PHC facilities. Therefore, individuals end up having 
high out-of-pocket expenditures in private pharma-
cies. This is the case for medicines for NCDs in 
Mozambique or NTDs in Peru; in those countries, 
some medicines are unaffordable, as the monthly cost 
exceeds the one-day’s-wage threshold [39]. Although 
insulin is only in Peru and not available in other 
countries, it is costly at up to 31 days’ wages.
The availability of functioning equipment and 
consumables is a significant problem in the three 
countries. When diagnostic tests are unavailable, 
transportation costs to another laboratory also 
increase patient’s out-of-pocket expenses. Essential 
equipment, such as blood pressure measurement 
devices and glucometers, with their respective con-
sumables, were not available or functioning in most 
facilities. Also, clear procedures for referrals are lack-
ing, and several problems impede transportation to 
a higher level for emergencies. Compounding these 
are clinical guidelines and training that are non- 
existent, insufficient or not adapted to local contexts 
and PHC. Adding to the challenges, are inadequate 
and insufficient education and information for 
patients, especially regarding pharmacological treat-
ment. Finally, patients’ data and information systems 
do not meet the needs of the individuals or the health 
Figure 2. Affordability of medicines for hypertension in the selected sites.
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systems; they are still limited, and registries are 
mainly paper-based files that do not allow for indivi-
dualised management or planning for necessary 
resources.
Although Mozambique, Nepal and Peru are very 
different LMICs in terms of cultural, socio-economic 
and health-system characteristics, they face similari-
ties and critical challenges to overcome at the PHC 
level in areas with vulnerable populations. Chronic 
conditions negatively affect people’s lives, and the 
economic consequences of health implications for 
productivity losses and higher out-of-pocket expenses 
further challenge effective high-quality care [40]. 
Improving PHC is essential for universal health cov-
erage in LMICs [41,42] and achieving SDG 3 [12]. 
This study shows that PHC is currently insufficiently 
prepared to manage NCDs and NTDs in these 
countries.
Previous studies highlight the challenges of 
managing chronic diseases in LMICs [22,43–46]. 
We applied a mixed-methods approach, previously 
implemented to assess the response of health sys-
tems to chronic diseases, using a systematic 
methodology adaptable to LMICs [20,23]. In con-
trast to other methods, e.g. the Service Availability 
and Readiness Assessment [47], we used 
a methodology for studying the health-system bar-
riers through various sources of information and 
the perspectives of policy makers, health authori-
ties, opinion leaders, health-care providers and 
patients. Therefore, the strength of our study is 
the depth of information, combining different 
views from participants at three health-system 
levels in three very different LMICs, using a set of 
‘tracer conditions’. Two of these conditions, dia-
betes and hypertension, have also been proposed 
as ‘tracer conditions’ for use with the Primary 
Health Care Impact, Performance and Capacity 
Tool (PHC-IMPACT) for monitoring PHC capacity 
in high- and middle-income countries [19]. Unlike 
the PHC-IMPACT, our study includes an NTD 
with chronic sequelae endemic to each setting. 
The tool used allowed us a comprehensive view of 
the problem through various elements of the health 
system. Moreover, future studies could include 
more topics to improve the breadth of topics 
Figure 3. Affordability of drugs for schistosomiasis (Mozambique) and neurocysticercosis (Peru), in number of days’ wages.
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covered, such as the availability of human 
resources, responsiveness and equity.
However, the approach we followed presents dif-
ferent challenges. First was the identification of infor-
mants at different levels of the health system, who 
could provide the necessary information. Another 
challenge was representativeness; such an approach 
favours depth over breadth, requiring information 
collection from different sources and informants to 
triangulate results. Also, by triangulating information 
at different levels, we corroborated the chosen facil-
ities as unexceptional and reflecting many of the 
problems found at PHC in the selected settings. 
Finally, the fieldwork team needed specific training 
in qualitative methods of data collection, which are 
unlike methods that use a standard structured 
questionnaire.
The overarching finding of this study is that cur-
rent systems fail to provide adequate chronic care for 
the populations they serve. A major need is to leap-
frog advancements at the PHC level in LMICs to 
address the so-called ‘quality gap’ [48–50]. In addi-
tion, the 40th anniversary of the Alma-Ata 
Declaration highlighted the need to focus on social 
aspects of health and disease [8,51] and build links 
and trust [52] between populations and PHC, to 
ensure that the health system is responsive to their 
needs. There is also the need to have stronger inte-
gration between PHC and the community [53] and 
their environment. PHC services in many LMICs face 
multiple challenges, and they must adapt to accom-
modate the growing demands for chronic care, guar-
anteeing high-quality care and continuity of care for 
the populations they serve, in the face of changing 
disease patterns and population needs.
Conclusion
By using different NCDs and NTDs as ‘tracer condi-
tions’, this study shows that PHC preparedness in 
Mozambique, Nepal and Peru is still insufficient to 
adequately address chronic diseases, with weaknesses 
in all six WHO building blocks. Beyond tangible 
elements that the health system and PHC must deli-
ver, health systems also need to address the issue of 
guaranteeing high-quality care to the populations 
they serve. Strengthening primary care is urgently 
needed, to guarantee the delivery and continuity of 
high-quality care for patients with chronic condi-
tions, and more so in LMICs, as they move towards 
the goal of achieving universal health coverage.
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